What does the Form 4 footnote reveal about the Alaunos Therapeutics (TCRT) share grant?

The footnote explains that the 6,032 Alaunos shares were issued in lieu of board fees. This means the director received company stock instead of cash for board service, underscoring that the transaction is compensation-related rather than a discretionary investment decision in the open market.

What is the reported price per share for the Alaunos Therapeutics (TCRT) stock award?

The Form 4 reports a price of $2.59 per share for the 6,032-share stock award to director Michael Allen Jerman. While this price is disclosed, the transaction represents compensation in stock form instead of cash fees, not an open-market purchase at that price.

Director at Alaunos (TCRT) receives 6,032-share stock award

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Alaunos Therapeutics, Inc. director Michael Allen Jerman received a grant of 6,032 shares of common stock on April 29, 2026, as a stock award issued in lieu of board fees. Following this compensation-related acquisition, he directly holds a total of 15,621 shares of Alaunos common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jerman Michael Allen

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	6,032	$2.59	$16K

Holdings After Transaction: Common Stock — 15,621 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares granted: 6,032 shares Price per share: $2.59 per share Total direct holdings: 15,621 shares

3 metrics

Shares granted 6,032 shares Stock award issued in lieu of board fees on April 29, 2026

Price per share $2.59 per share Reported transaction price for the 6,032-share award

Total direct holdings 15,621 shares Director’s direct Alaunos common stock holdings after the award

Key Terms

Grant, award, or other acquisition, in lieu of board fees, Common Stock

3 terms

Grant, award, or other acquisition financial

"transaction code description: Grant, award, or other acquisition"

in lieu of board fees financial

"Represents shares of common stock issued in lieu of board fees."

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

05/01/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jerman Michael Allen

(Last)

(First)

(Middle)

C/O ALAUNOS THERAPEUTICS, INC.

501 E. LAS OLAS BLVD. SUITE 300

(Street)

FORT LAUDERDALE

FLORIDA

33301

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/29/2026		A		6,032⁽¹⁾	A	$2.59	15,621	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of common stock issued in lieu of board fees.

	/s/ Michael, Jerman A	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Alaunos Therapeutics (TCRT) report for director Michael Allen Jerman?

Alaunos Therapeutics reported that director Michael Allen Jerman received a grant of 6,032 shares of common stock. The shares were issued as a stock award in lieu of board fees, reflecting compensation rather than an open-market purchase or sale.

Was the Alaunos Therapeutics (TCRT) director transaction an open-market buy or sell?

The transaction was not an open-market buy or sell. It was coded as a grant or award, with 6,032 shares of common stock issued to director Michael Allen Jerman as compensation in lieu of board fees, rather than through trading on the market.

How many Alaunos Therapeutics (TCRT) shares does director Michael Allen Jerman hold after this Form 4?

After the April 29, 2026 stock award, director Michael Allen Jerman directly holds 15,621 shares of Alaunos Therapeutics common stock. This total reflects his position following the grant of 6,032 shares issued in lieu of board fees as reported in the Form 4.